Convention Name Members
Debjit Chattopadhyay – Guggenheim Securities, LLC
Presentation
Debjit Chattopadhyay
Guggenheim Securities, LLC
Good morning, and thanks for becoming a member of Guggenheim’s 2026 Rising Outlook Biotech Summit. I’m Debjit, one of many therapeutic analysts, and my privilege to welcome our subsequent presenting firm Stable Biosciences and becoming a member of from Stable is Bo Cumbo, President and CEO. Thanks a lot on your time, Bo.
Alexander Cumbo
President, CEO & Director
Sure. Thanks, Debjit, and thanks, Guggenheim for invitation.
Debjit Chattopadhyay
Guggenheim Securities, LLC
So let’s do a really fast introduction to Stable. Clearly, the corporate has modified dramatically since you’ve got taken over?
Alexander Cumbo
President, CEO & Director
The corporate, it is an excellent little firm. We’ve about 120 staff. We market ourselves as a precision genetic medication firm. However primarily, we give attention to gene therapies. Our first 3 medicine are one for Duchenne. We’ll discuss loads about that immediately. Our second remedy is for Friedreich�s Ataxia and our third remedy is for CPVT, which is catecholaminergic polymorphic ventricular tachycardia.
We’ve a number of different applications as nicely, our subsequent program, dilated cardiomyopathies, TNNT2. After which we have now a complete capsid library and platform that we construct on supply as a result of to make gene remedy investable, once more, actually investable broadly talking, we have now to alter supply and supply is targeted on capsids, promoters, twin plasmids, manufacturing purity. So we spend time in all these areas as an organization and hopefully elevate everyone up.
Query-and-Reply Session
Debjit Chattopadhyay
Guggenheim Securities, LLC
Excellent. So on Monday, I imagine you set out a press launch aligning with the FDA on a registration research.
Alexander Cumbo
President, CEO & Director